ArticleCase reports in urology2026
Undifferentiated Castration-Resistant Prostate Cancer Successfully Treated With Carboplatin and Paclitaxel.
Article in Case reports in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Undifferentiated Castration-Resistant Prostate Cancer Successfully Treated With Carboplatin and Paclitaxel.Case reports in urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Castration-resistant prostate cancer (CRPC) is a heterogeneous and aggressive disease with limited treatment options, particularly in poorly differentiated cases that lack androgen receptor expression and progress rapidly even under conventional therapies. Here, we present a rare case of poorly differentiated CRPC that exhibited a remarkable response to carboplatin and paclitaxel therapy. Case Presentation: A 53-year-old man with metastatic, castration-sensitive prostate cancer (cT3bN1M1b, PSA 9.39 ng/mL, Gleason 4 + 5) underwent androgen deprivation therapy using bicalutamide and leuprorelin. Nine months later, he developed CRPC, despite undetectable PSA levels. A supraclavicular lymph node biopsy revealed a poorly differentiated carcinoma. Immunohistochemistry was negative for PSA and NKX3.1 and positive for CK5/6. These results excluded neuroendocrine carcinoma and supported a diagnosis of undifferentiated carcinoma. Systemic chemotherapy with carboplatin (area under the curve, five) and paclitaxel (200 mg/m Conclusion: This case highlights the potential efficacy of carboplatin and paclitaxel in treating poorly differentiated CRPC, suggesting the need for further investigation into platinum-based regimens for aggressive prostate cancer variants.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.